Podcasts about Relevance

 Lex chats with Edward Woodford - CEO of Zerohash. They discuss Zerohash's growth, the rise of stablecoins, and the evolving fintech landscape. Edward explains how stablecoins now make up half of Zerohash's volume, highlights regulatory shifts in the U.S. and abroad, and explores the distinction between crypto and stablecoins. The conversation covers usability challenges, emerging payment use cases, and the future of embedded finance, emphasizing the need for regulatory clarity and collaboration between fintechs and traditional financial institutions. Notable discussion points: 1. Stablecoins Overtake Crypto in Volume: Stablecoins now make up over 50% of Zerohash's volume, driven by regulatory clarity and real-world use cases like payments and treasury. Institutions prefer them for their centralized control and ease of integration.2. Brokerage and Payments Are Converging: Zerohash sees strong demand across brokerage and payment rails, with banks and fintechs embedding stablecoin infrastructure. Global payouts, account funding, and subscriptions are key growth areas despite UX friction.3. Regulatory Climate Is Rapidly Improving: U.S. policy has shifted from regulatory overreach to bipartisan support for stablecoin legislation. This change is unlocking institutional adoption, with banks now moving aggressively into crypto and digital assets. MENTIONED IN THE CONVERSATION Topics: Zerohash, MoonPay, Transak, Ramp, Stripe, BlackRock, Franklin Templeton, Hamilton Lane, Morgan Stanley, Charles Schwab, SoFi, Uniswap, fintech, web3, digital assets, blockchain, tokenization, rwas, stablecoin, crypto, regulation ABOUT THE FINTECH BLUEPRINT 

“When you protect your team from the storm, you create space for focus, trust, and innovation.”In this episode of Business is Human, Rebecca Fleetwood Hession discusses what it really means to “hold up the umbrella” as a leader. It's more than just shielding your team from distractions, it's a principle rooted in neuroscience, real-world leadership, and emotional awareness. Rebecca reflects on the importance of psychological safety, shares lessons from great managers, and calls for a return to people-first leadership, especially in today's pressure-filled business climate.In this episode, you'll learn:Why psychological safety fuels creativity, innovation, and better decision-makingHow to filter out noise and offer context that truly matters to your teamThe difference between performative gestures and real human connectionThings to listen for:(00:00) Intro(00:43) Merchandise and promotions(01:41) Holding Up the Umbrella(03:50)) The role of psychological safety(04:21) The pendulum of business focus(05:32) Transparency and information overload(07:40) Science behind leadership and safety(10:14) Challenges for middle managers(14:55) Starbucks experience and corporate mandates(21:46) Leading together as a teamConnect with Rebecca:https://www.rebeccafleetwoodhession.com/

We're coming to you live from Permissionless! We cover Polymarket's resurgence and cultural relevance, PumpFun's consumer-driven strategy and funding ambitions, and the evolving role of trading bots and prosumer apps. We also explore CEX onchain strategies, Robinhood's approach to crypto, and how IPO trends may reshape the industry's capital markets. Thanks for tuning in! As always, remember this podcast is for informational purposes only, and any views expressed by anyone on the show are solely their opinions, not financial advice. -- Katana is a DeFi-first chain built for deep liquidity and high yield. No empty emissions, just real yield and sequencer fees routed back to DeFi users.  Pre-deposit now: Earn high APRs with Turtle Club https://app.turtle.club/campaigns/katana or spin the wheel with Katana Krates https://app.katana.network/krates -- Ledger, the global leader in digital asset security, proudly sponsors 0xResearch! As Ledger celebrates 10 years of securing 20% of global crypto, it remains the top choice for securing your assets. Buy a LEDGER™ device now and build confidently, knowing your precious tokens are safe. Buy now on https://shop.ledger.com/?r=1da180a5de00. -- Marinade is the premier staking delegation platform on Solana, bringing billions in liquidity and security to the Solana network, and connecting SOL holders to the best staking rates.  Since launching in 2021, Marinade has expanded their suite of products to provide solutions for both DeFi users and TradFi, including liquid and native staking, as well as direct enterprise integrations.  To learn more about Marinade, follow the link below: https://marinade.finance/?utm_source=blockworks&utm_medium=partnerships&utm_campaign=podcast  -- Follow Dan: https://x.com/smyyguy Follow Ryan: https://x.com/_ryanrconnor Follow Danny: https://x.com/defi_kay_ Follow Boccaccio: https://x.com/salveboccaccio Follow Blockworks Research: https://x.com/blockworksres Subscribe on YouTube: https://bit.ly/3foDS38 Subscribe on Apple: https://apple.co/3SNhUEt Subscribe on Spotify: https://spoti.fi/3NlP1hA Get top market insights and the latest in crypto news. Subscribe to Blockworks Daily Newsletter: https://blockworks.co/newsletter/ Join the 0xResearch Telegram group: https://t.me/+z0H6y2bS-dllODVh -- Timestamps: (0:00) Introduction (0:52) Polymarket's New Raise (9:51) Ads (Katana & Legder) (10:28) PumpFun's Social Strategy (19:30) Ads (Katana & Legder) (20:35) Trading Bots & Prosumer Apps (27:31) PUMPs Impact on Solana (32:03) Marinade Ad (32:35) CEX Onchain Product Offerings (41:58) Dunk Boccaccio and Danny -- Check out Blockworks Research today! Research, data, governance, tokenomics, and models – now, all in one place Blockworks Research: https://www.blockworksresearch.com/ Free Daily Newsletter: https://blockworks.co/newsletter -- Disclaimer: Nothing said on 0xResearch is a recommendation to buy or sell securities or tokens. This podcast is for informational purposes only, and any views expressed by anyone on the show are solely our opinions, not financial advice. Boccaccio, Danny, and our guests may hold positions in the companies, funds, or projects discussed.

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Rachel Maddow reviews the cast of characters that staff important national security roles in the Trump administration, and whose lack of qualifications for their jobs matters even more now that Donald Trump's bombing of Iran has raised the threat level for Americans everywhere in the world.

If you've ever wondered whether your nonprofit fundraising data is a treasure chest or a digital junk drawer, Greg Warner is here with a flashlight, a map, and a pickaxe. In this entertaining conversation, Greg—CEO of MarketSmart and creator of the Fundraising Report Card—joins host Julia Patrick to dissect the murky waters of metrics and help nonprofits move from guesswork to grounded strategy.Greg kicks off with the backstory: MarketSmart's 17-year evolution into a marketing automation firm helping nonprofits identify, qualify, and steward major and legacy donors. ‘The Fundraising Report Card', born from this journey, now offers nonprofits a simplified yet powerful lens into donor behavior—showing not just what happened, but what it means.Here's the twist: until now, this tool has been free. But with over 27,000 users and a mountain of benchmark data, Greg's team is rolling out a more robust version—with peer comparisons so relevant, they make national averages look like vague horoscopes.And it's about time. “Relevance creates resonance,” Greg shares, “But irrelevant data creates dissonance.” Nonprofits have long been running on emotional narratives and gut instincts. Greg invites you to reframe the conversation using donor lifetime value, retention data, and institutional memory—all quantified, all visual.Julia comments how too many development pros spend two days prepping board reports for seven minutes of attention. Greg's fix? Collaborative tools baked into the new version of the app, enabling real-time, cross-functional dialogue. Because why silo data when you can democratize it?Want to stop flying blind and start mining gold? This episode is your blueprint. 00:00:00 Intro and welcome to Greg Warner 00:01:13 What is the Fundraising Report Card? 00:03:56 Gut instinct vs. meaningful metrics 00:06:33 Leaky buckets and donor attrition 00:08:34 Who really uses the data—and how 00:10:36 Collaboration tools and institutional memory 00:12:14 Why clean data matters 00:14:07 The power of relevant peer benchmarks 00:16:34 Lifetime value explained 00:18:54 Emotion vs. analytics in fundraising 00:22:22 Donor files and hidden gold 00:27:16 Final thoughts and educator access #FundraisingData #DonorAnalytics #TheNonprofitShowFind us Live daily on YouTube!Find us Live daily on LinkedIn!Find us Live daily on X: @Nonprofit_ShowOur national co-hosts and amazing guests discuss management, money and missions of nonprofits! 12:30pm ET 11:30am CT 10:30am MT 9:30am PTSend us your ideas for Show Guests or Topics: HelpDesk@AmericanNonprofitAcademy.comVisit us on the web:The Nonprofit Show

Josh Bush previews his message for the Sunday evening service at the 2025 National Convention. Josh will explore the theme, “When God Calls, Will You Accept the Mission?” from Jonah 1. Josh is pastor of Cross Point Free Will Baptist Church in Wichita, Kansas. #NAFWB #BetterTogether #AcceptTheMission

Images of the yearly Hajj (annual pilgrimage to Makkah) continue to capture the attention of the world. As people witness the synchronization of actions and purpose of millions of pilgrims, they experience amazement and wonderment. People often ask, “Why is the Hajj important?” or “What is the purpose of pilgrimage rituals in this day and age?”In this paper, we discuss the power of rituals in general and focus on the various benefits and significance of the Hajj rituals in particular. In the course of this discussion, we embark on a whirlwind tour of relevant material from anthropology, psychology, theology, jurisprudence, exegesis, philosophy, and—most importantly—Islamic spirituality.

In this episode of Leading You, I’m joined by Tony Frost—executive coach, keynote speaker, company director, and author of The Professional. With an award-winning career spanning law, accounting, and executive leadership, Tony shares a grounded, forward-thinking take on how to stay relevant in a world of constant change. We explore the essential human skills that will never go out of date—emotional intelligence, storytelling, self-awareness, humility—and how to develop them to become the kind of leader others want to follow. Whether you’re leading a team, a business, or yourself, this conversation offers clear, practical strategies to help you lead with confidence, clarity, and real connection. What we cover: Why soft skills are now business-critical The three timeless traits followers want from leaders How humility helps you build trust and negotiate better Why storytelling is your leadership superpower “Relevance deprivation syndrome” and how to avoid it How to identify your ‘prime capabilities’ and ‘human tasks’ Four dangerous mindsets that make leaders obsolete How to embrace lifelong learning (without burning out) Using AI as a career tool—not a threat The role of feedback, reverse mentoring, and self-leadership in growth Timestamps: 00:00 – Welcome to Leading You 00:44 – Meet Tony Frost: From Lawyer to Executive Coach 01:17 – The Urgency of Future-Proofing Your Career 01:54 – AI’s Impact on the Legal Industry 03:15 – Essential Skills for Leaders in an AI-Driven World 07:47 – Emotional Intelligence: The New Competitive Advantage 10:29 – Dangerous Mindsets for Leaders to Avoid 14:49 – How to Embrace Lifelong Learning Without Overwhelm 17:09 – Reverse Mentoring & Learning from the Next Generation 19:04 – Final Takeaways and Next Steps for Future-Ready Leadership Links:Get the Clarity Compass Mini Program Connect with Julie:LinkedIn: https://www.linkedin.com/in/julie-hyde/Instagram: @juliehydeleadsWebsite: https://juliehyde.com.auConnect with Tony Frost:Website: https://frostleadership.com.au/LinkedIn: https://www.linkedin.com/in/tony-frost-cmc/Buy The Professional: https://frostleadership.com.au/my-book/See omnystudio.com/listener for privacy information.

Get ready for an episode packed with real talk

Join me for a lively conversation with Ryan Deiss as we unravel the mysteries of influencer marketing. Explore the world of micro-influencers and mega-stars, and discover which path leads to greater marketing success. From the power of niche audiences to the pitfalls of chasing fame, get ready for practical insights and expert advice to level up your influencer game. Tune in for a discussion filled with tips and real-world experiences to guide you through your journey!Highlights:"There's a point where somebody crosses over from influencer to celebrity. You're paying more for reach and giving up actual influence.""As your brand gets bigger, you've got no choice but to go there. It's why big brands do Super Bowl ads—they need the reach.""An authentic endorsement goes a long way. If the influencer genuinely uses and likes your product, it resonates with their audience."Timestamps:01:00 - AMA's Study on Influencer Marketing ROI02:22 - Targeting Micro-Influencers for Specific Products04:44 - Balancing Reach vs. Relevance in Influencer Selection06:06 - Niche Audiences and Higher ROI07:31 - Calculating (ROAS) for Influencer Campaigns08:58 - Famous Celebrities vs. Influencers10:24 - Maximizing ROI with Newsletter Advertising11:51 - The Trade-off Between Fame and Influence13:12 - Multi-Touch Campaigns and Long-Term Influencer Partnerships14:40 - Direct Outreach vs. Using Influencer AgenciesCONNECT • Ask Roland a question HERE.RESOURCES:• 7 Steps to Scalable workbook • Get my book, Zero Down, FREETo learn more about Roland Frasier

This is a compressed version of the 2013 series of shows on Chant It Down called the system tentacles. This was a live presentation in June of 2022 unreleased to this feed. .A basic, but stepwise progression of layers of the system to break through and get unhinged from, to see if you're truly awake in this world.This is the basic tenants of Chant It Down. Even if this is an old show, and there are many unrelated shows on this feed, these basic tenants stay the same. For a better visual experience: https://rumble.com/v3muryr-removing-the-system-tentacles-presentation.htmlShow website:⁠https://www.chantitdownradio.com/⁠Youtube: ⁠https://www.youtube.com/channel/UCmTlBzFViiv58N4_K9On0UQ⁠Instagram: ⁠https://www.instagram.com/chantitdown/⁠Telegram:⁠https://t.me/chantitdown⁠Odysee: ⁠https://odysee.com/@chantitdownradio:c⁠Rumble: ⁠https://rumble.com/user/Chantitdownradio⁠Please help support the show. Subscribe, leave reviews, help algorithms find the show. Support the show if possible.Support Luemas in his new documentary join Patreon and get the extra show: Afterthoughts : ⁠https://www.patreon.com/Luemas⁠⁠https://www.chantitdownradio.com/store.html⁠Chant it down t-shirts: https://chant-it-down-store.creator-spring.com/listing/chant-it-down-logo

Fighting isn't just physical combat – it's a journey that reveals who one is at their core. This revelation forms the backbone of my passionate breakdown of what makes certain fighters special in their approach to MMA.After briefly recapping UFC Atlanta, where Rose Namajunas proved her technique translates perfectly to 125 pounds and Kamaru Usman secured a run-of-the-mill victory over Joaquin Buckley, I dive into Jon Jones' latest attention-seeking behavior. His calls for a Francis Ngannou fight while avoiding Tom Aspinall expose a calculated strategy of pursuing unrealistic matchups to avoid legitimate contenders. listen to me explain why the economics simply don't work!The heart of this episode explores the upcoming Hill vs. Roundtree fight through a different lens. Khalil Roundtree embodies what I most admire in fighters – those who discover martial arts as a path for personal transformation. Unlike fighters born into combat sports traditions or those who join to escape trouble, Roundtree represents athletes who find in fighting a means to channel emotional energy into disciplined growth. His journey from someone just looking to lose weight, to a world traveler training in places such as Thailand shows how fighting becomes more than competition – it becomes IDENTITY.Want to see more of my analysis? Follow me on Instagram @cheymynameee and subscribe to catch every episode where I break down the deeper meaning behind the sport we all love!

Ben and Brent kick off The FAN Morning Show's final hour of the week talking Blue Jays and the team's recent run of form. Sportsnet's own Shi Davidi joins the conversation to discuss Toronto's main needs as they near the midway mark of the season. He looks into how to address the starting rotation, why moving Vladimir Guerrero Jr. to third in the order has payed off, who (or what) could carry this team to the postseason, and the odd man out in the Jays' soon to be overcrowded outfield. To end the week, the boys revisit Connor McDavid's situation in Edmonton as he heads into the final year of his contract (25:29). Ben and Brent investigate what could sway his decision to stay in Edmonton, what the organization could do to make sure he's happy, and where his other main destinations might be.The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the position of Rogers Sports & Media or any affiliates.

https://www.coachingforrelevance.com/https://www.amazon.com/Bring-Freedom-Potential-Overcoming-Soaring-ebook/dp/B0D3BVD1GY/ref=sr_1_1?crid=3TGTLR44A8JNT&dib=eyJ2IjoiMSJ9.-tS4GlU7CqiCwISeIYoHV_Y1sqCG5MioC8ZbYLo38kAM8A2JPTUFRLp0iE4NntW0HsVqZEHupeHX2wieWWjUPbxo39Cw3mao9Hiv4MHq03zLyylIvKZWDVc9SulEwcwXh1mAiMAHexLsWrS2wJnVjgxLpv0wOi4JQIVoWW4h4aYYk509fMxo880flRWiHCF3ldphFkuTU5Ym8NNNjosdDsuoj04Mr3mU8L-niN4409w.v9J0csZcatbaAlDEgPY0pVS3lXV2XahICl8-gkpNayU&dib_tag=se&keywords=randy+swaim&qid=1715269499&sprefix=randy+swai%2Caps%2C312&sr=8-1 Listen to us live on mytuner-radio, onlineradiobox, fmradiofree.com and streema.com (the simpleradio app)https://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+networkhttps://www.fmradiofree.com/search?q=professional+podcast+networkhttps://streema.com/radios/search/?q=podcast+business+news+network

“Changing jobs or zip codes won't fix a soul-level misalignment.”In this episode of Business is Human, Rebecca Fleetwood Hession shares a heartfelt and energized reflection on how true transformation doesn't come from external changes, but from doing the inner work of aligning with your authentic identity. From prayerful moments on her patio to spontaneous blessings and first-class upgrades, Rebecca's recent experience planning a trip to Italy becomes a metaphor for how peace, joy, and clarity follow when you stop striving and start thriving. Through stories, scripture, and soulful questions, she invites listeners to move beyond burnout, fear, and false metrics of success by getting quiet, tuning into their nervous system, and reconnecting with God-given identity.In this episode, you'll learn:Why burnout often signals striving, not alignmentWhy the “Sunday scaries” might be more about identity than employmentThe difference between “thriving tired” and “striving tired”Things to listen for:(00:00) Intro(00:43) Excitement and nervous system activation(01:04) Vacation mindset shift(02:58) The Italy trip blessing(04:51) The story of the birthday boots(05:54) The illusion of escape(07:41) Finding your true identity(13:36) The power of prayer(17:34) Leadership and nervous system regulationConnect with Rebecca:https://www.rebeccafleetwoodhession.com/

Explore the cutting-edge world of AI-driven product discovery in e-commerce with this episode's guest, Peter Curran, General Manager of Commerce at Coveo. This episode examines the evolving role of AI technologies, including retrieval-augmented generation, in enhancing the online shopping experience.  From tackling common challenges on platforms like Instagram to the importance of trust in AI adoption, Peter shares compelling examples that illustrate AI's impact on contextual relevance and user experience. Join us as we explore the future of shopping and the collaborative approach required to navigate the rapidly evolving landscape of agentic commerce. Show Highlights: Overcoming e-commerce challenges using AI technologies like retrieval-augmented generation (RAG). The role of AI in improving contextual relevance and providing a seamless shopping experience. The importance of trust and agility in AI adoption within e-commerce platforms. The significance of comprehensive content and user-generated feedback in bridging product discovery and purchase decisions. Examination of how social media influences product discovery, but often does not complete the purchasing journey. Follow and Review: We'd love for you to follow us if you haven't yet. Click that purple '+' in the top right corner of your Apple Podcasts app. We'd love it even more if you could drop a review or 5-star rating over on Apple Podcasts. Simply select “Ratings and Reviews” and “Write a Review,” then a quick line with your favorite part of the episode. It only takes a second, and it helps spread the word about the podcast. Supporting Resources: Peter Curran on LinkedIn: https://www.linkedin.com/in/petercurran/  Coveo: https://www.coveo.com/en  Learn more about Agentforce for Commerce: https://www.salesforce.com/commerce/ai/  Join the Commerce Cloud Community: https://sforce.co/commerce-crew *** Episode Credits If you like this podcast and are thinking of creating your own, consider talking to my producer, Emerald City Productions. They helped me grow and produce the podcast you are listening to right now. Find out more at https://emeraldcitypro.com. Let them know I sent you.

Why does a 72-year-old play about 333-year-old witch trials still feel urgently relevant today? Arthur Miller's The Crucible has become theater's ultimate evergreen story, because it captures something timeless and terrifying about human nature—our willingness to destroy each other when fear takes hold.When Miller's play premiered on January 10, 1953, audiences immediately understood it wasn't really about Salem. This was Miller's bold response to McCarthyism, a thinly veiled critique of Senator Joseph McCarthy's communist witch hunts that were tearing through American society. Miller had taken the Salem witch trials and transformed them into a mirror, forcing 1950s America to confront its own capacity for panic and persecution.But here's what makes The Crucible truly remarkable: it didn't stop being relevant when McCarthyism ended. In our current era, when we're so quick to label people as enemies and deny their humanity, Miller's allegory feels more essential than ever. The play's central question—what happens when a community turns against itself in search of hidden enemies—remains one of the most important questions we can ask.Whether you know the play from school, the stage, or the screen, whether you have family who lived through the Red Scare or ancestors who witnessed Salem's trials, The Crucible speaks to something universal about the human condition. It reminds us that in times of crisis, we all face the same choice: Will we stand with the mob, or will we find the courage to stand for justice?Buy the book: The Red Scare by Clay RisenBuy the Play: The Crucible by Arthur MillerBuy the book: The Enemy Within by John DemosHelp Us Build Our Patreon Community⁠⁠The Thing About Witch Hunts WebsiteThe Thing About Salem WebsiteCheck out our new podcast: The Thing About Salem on YouTube!⁠⁠Sign up for our Newsletter⁠⁠Donate to The Thing About Witch Hunts Fieldwork Fund

http://www.sherylkline.com/blogIn the latest Fearless Female Leadership interview, I had the incredible opportunity to speak with Kimberly Evans, Executive Vice President, Head of Corporate Sustainability, Inclusion, and Social Impact at Northern Trust. Kimberly's story is a powerful testament to the strength of purpose, the power of people-centered leadership, and the importance of seeking value over validation.Rooted in humble beginnings, Kim shared how her mother's example of selflessness and generosity shaped her entire approach to leadership. A defining childhood moment—watching her mother put groceries back at checkout—fueled her lifelong “why”: to succeed so her mom would never have to go without again. That clarity of purpose has guided Kimberly through the financial services industry, where she's often been the only woman—and sometimes the only person of color—in the room.Kimberly emphasized that success doesn't require fitting a mold, but rather leveraging resilience, adaptive capacity, and emotional intelligence. She challenges leaders to mine for talent where others don't look, build teams around transferable skills, and invest in people, not résumés. Her mindset of “let your why find the way” and her philosophy of seeking value versus validation are lessons for leaders at every level.Key takeaways from the interview:0:02:34 – Kim's mother modeled selflessness and community care, even when resources were scarce—a lesson that shaped her leadership philosophy.0:07:53 – At just six years old, Kim vowed to succeed so her mother would never have to put groceries back again—a promise that became her lifelong "why."0:08:46 – Lacking a traditional finance background, Kim leaned on mindset, mentors, and resilience to thrive in a male-dominated industry.0:13:54 – The current talent landscape demands adaptive capacity over rigid experience; success belongs to the curious, the coachable, and the resilient.0:15:01 – Talent is everywhere—opportunity is not. Leaders must “mine for talent” in unexpected places and value lived experience as much as formal credentials.0:17:35 – Focus on people who can “learn as they go and grow”—these are the leaders of the future in an AI-disrupted world.0:21:09 – Kim's personal framework: the 3+1 R's—Readiness, Resilience, Relevance, and Relationships.0:22:37 – Leaders should seek value, not validation; external approval is fleeting, but knowing your worth creates lasting confidence and clarity.0:24:08 – You may not control the validation you receive—but you always control the value you deliver.0:25:00 – True growth happens outside of comfort zones. Kim reminds us: stay in the game, trust your “why,” and lead with heart.If you're interested in being featured on the Fearless Female Leadership podcast, or you're a leader looking to gain clarity on ‘what's next', how to build more cohesive and high-performing teams, and lead with greater confidence and influence, let's have a confidential conversation. Cheering you on always!– Sheryl

Welcome to "Messenger to Messiah," our exploration of the timeless message of Malachi on the Gospel Spice podcast. In this first lesson of our six-part series, Stephanie Rousselle, our teacher, walks us through the timely relevance of the Book of Malachi for our contemporary generation. Our series aims to dive into the intricacies of Malachi's message, with an emphasis on its pertinence to today's societal landscape. Stephanie approaches this study with humility and the hope that it serves you meaningfully! You are invited to purchase the workbook that contains everything you need to take your experience of the Book of Malachi deeper! For each of the six lessons, you will find a complete listening guide, questions to go deeper (on your own, with a friend, or a group), as well as a worksheet to study further themes. Go to https://www.gospelspice.com/malachi for more. And BONUS! We're giving you all the workbook content for THIS EPISODE, the first in the series, completely for FREE! Go to  https://www.gospelspice.com/malachi to download it as our gift to you. The Book of Malachi, the last book of the Old Testament, addresses the pressing question, "Lord, how have you loved us?" This question, emerging from a context of hardship and perceived abandonment, resonates with the existential uncertainties we often face. This inquiry transcends time, mirroring our own struggles to see God's love during difficult times. Malachi's name, meaning "my messenger," underscores the significant role of his prophecy. The etymology of the name is echoed in Malachi's life, calling and message. Its implications draw parallels between earthly and angelic messengers throughout the Old Testament. We are also offered a detailed historical backdrop, mapping the trajectory from Moses through the judges, kings, and the era of Babylonian exile, leading to the restoration under leaders like Zerubbabel, Ezra, and Nehemiah. This historical perspective enriches our understanding of Malachi's audience—people who had endured a tumultuous past yet stood at the cusp of spiritual revival. Malachi interprets the juxtaposition of God's love for Jacob and rejection of Esau. The discourse around love ('ahav' in Hebrew) emphasizes God's unwavering choices and the perceived enmity of Esau's lineage, the Edomites, against Israel. In looking forward, Malachi's prophecy foreshadows the role of messengers like John the Baptist, preparing the way for Jesus, who is the ultimate Messenger. This anticipation reflects our own call to serve as messengers in the world today, spreading God's love and laying the groundwork for spiritual awakening in the Name of Jesus, our Christ and King. Stephanie concludes by encouraging us to recognize God's love in both blessings and adversities. She challenges us to list God's blessings, seeing His hand in every circumstance, much like Paul's thorn that became an opportunity for divine glorification. This series is an invitation to embrace the words of Malachi not merely as historical accounts, but as vibrant truths applicable in our lives. Malachi urges us to become aware of our roles as God's messengers today. You are invited to journey with us through this series and to seek to understand how God's love permeates every aspect of our existence. We invite you to check out the first episode of each of our series, and decide which one you will want to start with. Go to gospelspice.com for more, and go especially to gospelspice.com/podcast to enjoy our guests! Interested in our blog? Click here: gospelspice.com/blog Identity in the battle | Ephesians https://www.podcastics.com/episode/74762/link/ Centering on Christ | The Tabernacle experience https://www.podcastics.com/episode/94182/link/ Shades of Red | Against human oppression https://www.podcastics.com/episode/115017/link/ God's glory, our delight  https://www.podcastics.com/episode/126051/link/   Support us on Gospel Spice, PayPal and Venmo!

Is your team and organization future-ready? The future of work is here. In this episode of "Empowerment Minutes," we discuss why re-skilling is essential for future-ready leadership. She'll share actionable strategies to prepare yourself and your team for what's next, including: Why employees need to reskill and the key skills that matter most. Three ways to build a culture of continuous learning. Tools and programs to help your leaders thrive Tune in now on Amazon Music, iTunes, Podbean, Spotify, YouTube Music, or your favorite podcast platform and learn how to empower your team for future success!  

No matter what anyone says, cold calling isn't dead. The digital world just made it harder than it used to be.This is why I'm revisiting episode 1730 with my guest, Gabe Lullo. He shares his expertise and insights on cold calling and sales strategies in this ever-evolving landscape. Is Cold Calling Dead?Addressing the prevalent debate, Gabe firmly asserts that cold calling is far from dead.Supported by data and real-life experience, he emphasizes the effectiveness of cold calling in qualification, call-to-action, and appointment setting, debunking the myths surrounding its relevance in the current sales environment.Modern Sales ApproachGabe stresses the importance of an omnichannel approach, integrating call, email, and social platforms to establish meaningful and relevant connections with prospects. He emphasizes the need for high-volume activity paired with a relevant message, highlighting the power of personalization and the human touch in driving engagement.Strategies for Relevant MessagingGabe delves into the nuances of crafting relevant messaging, emphasizing the importance of relevance over mere personalization. He shares insights on identifying and leveraging data providers to tailor messages according to the prospects' specific verticals and ICPs, and the significance of using technology for optimizing communication channels.The Role of Human Touch and EmpathyWe explore how human touch, empathy, and personalized, relevant communication set sales professionals apart in the current market. Gabe emphasizes the need to sound like a human, not an AI bot, illustrating how to engage prospects effectively and foster genuine connections.Optimizing SequencingGabe challenges the traditional sequence approach, advocating for a burst of activities across multiple channels rather than drawn-out, segmented sequences. He highlights the significance of engagement and conversation to drive effective communication, emphasizing the need to adapt and modernize sales strategies.Mastering the Cold CallGabe shares valuable insights into mastering the art of cold calling, stressing the need for extensive training and knowledge of objection handling. Understanding and anticipating objections empowers sales professionals to navigate conversations effectively and win at cold calling."Relevance matters more now. That human touch is what sets individuals apart from the low-hanging fruit." - Gabe Lullo.ResourcesConnect with Gabe on LinkedIn.If you like more guidance with improving your sales skills, join my Sales Mastermind Class.Sponsorship OffersThis episode is brought to you in part by Hubspot.With HubSpot sales hubs, your data tools and teams join a single platform to close deals and turn prospects into pipelines. Try it for yourself at hubspot.com/sales.2. This episode is brought to you in part by LinkedIn.Are you tired of prospective clients not responding to your emails? Sign up for a free 60-day trial of LinkedIn Sales Navigator at

We're joined by professor and author Sami Al Daghistani to explore the life and thought of Al-Ghazali, a prominent figure in Islamic intellectual history. We delve into Al-Ghazali's multifaceted contributions to Islamic law, philosophy, and theology, highlighting his major works, such as "The Revival of Religious Sciences" and "Deliverance from Error and the Beginning of Guidance." We examine his ethical system of economic thought, existential crises, and his impact on modern economic theory, ethics, and the philosophical landscape. The conversation also touches upon the relevance of Al-Ghazali's ideas in today's global economy and ethical contexts.01:00 Introduction01:28 Who Was Al-Ghazali?04:04 Al-Ghazali's Journey and Spiritual Crisis07:33 Al-Ghazali's Intellectual Contributions and Influence09:59 The Philosophical Environment of Al-Ghazali's Time15:12 Al-Ghazali's Ethical Economics and Pursuit of Happiness29:24 Al-Ghazali's Views on Wealth and Economic Engagement30:49 Active Engagement in Society and Wealth31:44 Critiques of Materialism and Balance32:56 Ethical Economics and Wealth Distribution35:04 Islamic Perspectives on Capitalism and Socialism39:02 Modern Islamic Economics and Finance43:24 Connections to Western Philosophers46:52 Historical Contributions and Misconceptions51:47 Relevance of Classical Thinkers Today01:00:09 Conclusion and Contact InformationSami Al Daghistani is Associate Senior Lecturer in Contemporary Islamic Studies at Lund University, Associate Faculty at the Brooklyn Institute for Social Research, and Research Scholar at Columbia University's Middle East Institute. His research explores intersections of Islamic economics, ethics, law, and the environment through interdisciplinary and historical approaches. He is the author of The Making of Islamic Economic Thought (Cambridge, 2022) and Abū Ḥāmid al-Ghazālī's Ethical Teachings (Anthem, 2021), among other works. Sami holds a PhD from Leiden University and previously held fellowships in Oslo and New York. Hosted by: Mikey Muhanna

Relevance For Today Upcoming Discipleship Episodes Summer 2025 Episode 354 My plan for this year (2025) is to highlight impactful episodes designed to help draw people closer to the Lord. We'll be tackling some crucial topics—starting with a full series on salvation, followed by Bible Translations, Bible Study Tips, Key Bible Verses, discovering our Purpose as Christians, and how to live a Christ-like life. The goal is to make each episode a tool not only for personal growth but also for training and equipping others to grow in Christ. You have my full permission to use these episodes in small groups, Bible studies, discipleship training sessions, and more. Don't forget to share, subscribe, and leave some feedback—I'd love to hear how these messages are impacting your life. Thanks! Facebook: Stephen Lewis Relevance For Today Facebook: Stephen Lewis Relevance For Today rftministry@gmail.com Instagram: @relevancefortoday TikTok: @stephenlewisrft YouTube Channel Relevance For Today Stephen Lewis

Welcome to this week in NoCode + AI! Host JJ Englert chats with Jacky, co-founder and co-CEO of Relevance AI, who discusses their recent $24 million series B funding to scale their AI workforce. Jacky showcases a live demo of their platform, highlighting how AI agents evolve beyond single-purpose bots. Key topics include the world's largest hackathon by Bolt, Softr's upcoming launch of native databases, and the controversy around Apple's iOS 26 design. Don't miss Jacky's deep dive into building AI teams, managing autonomous agents, and optimizing no-code solutions.Learn more about Relevance AI: https://relevanceai.com/

Podcast: Control Amplified: The Process Automation Podcast (LS 25 · TOP 10% what is this?)Episode: Modern SCADA: ensuring safety, relevance and conveniencePub date: 2025-06-11Get Podcast Transcript →powered by Listen411 - fast audio-to-text and summarizationSCADA applications are responsible for far more than facilitating real-time process monitoring and alarm management. The process history they compile over time is critical to providing the data-driven insights that industry relies on when optimizing their systems to control costs, maximize uptime and increase the life of infrastructure. Modern SCADA systems must ensure data is safe, relevant and easily shareable with a company's own team or third-party reporting solutions, business systems and artificial intelligence (AI) platforms. Control Amplified talked to Chris Little, media relations director, Trihedral Engineering, about straightforward principles to ensure that your SCADA data is ready to go to work.The podcast and artwork embedded on this page are from ControlGlobal, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.

In this episode, Mish and Joe discuss Goldberg's relevance in 2025, the generational disconnect between older wrestling stars and today's younger audience, and the potential of new characters like Mr. Iguana. They analyze the shift in Ron Killings' character and the challenge of engaging current wrestling fans. The conversation also touches on the behind-the-scenes dynamics and future possibilities for wrestling collaborations and promotions like WWE, AEW, and NWA. Plus, there's a humorous look at Kenny Omega's recent controversial segment on AEW.00:00 Goldberg's Relevance in 202502:04 Nikki Bella's Podcast and Heritage06:55 The Bella Twins' Impact on Wrestling27:21 Mr. Iguana's WWE Debut36:13 Ron Killings' New Direction44:05 Doubts About Ron Killings' New Character45:02 The Rise and Fall of Chapel Row46:59 Wrestling Fans and Character Complexity51:51 The Undertaker's New Podcast55:02 NWA Streaming on Roku58:26 American Gladiators Featuring Wrestlers01:06:10 WWE's Expensive Priority Pass01:12:23 AEW's Injury Angles and Criticism01:24:14 Concluding Remarks and ShoutoutsBecome a supporter of this podcast: https://www.spreaker.com/podcast/wrestling-soup--1425249/support.

https://www.coachingforrelevance.com/https://www.amazon.com/Bring-Freedom-Potential-Overcoming-Soaring-ebook/dp/B0D3BVD1GY/ref=sr_1_1?crid=3TGTLR44A8JNT&dib=eyJ2IjoiMSJ9.-tS4GlU7CqiCwISeIYoHV_Y1sqCG5MioC8ZbYLo38kAM8A2JPTUFRLp0iE4NntW0HsVqZEHupeHX2wieWWjUPbxo39Cw3mao9Hiv4MHq03zLyylIvKZWDVc9SulEwcwXh1mAiMAHexLsWrS2wJnVjgxLpv0wOi4JQIVoWW4h4aYYk509fMxo880flRWiHCF3ldphFkuTU5Ym8NNNjosdDsuoj04Mr3mU8L-niN4409w.v9J0csZcatbaAlDEgPY0pVS3lXV2XahICl8-gkpNayU&dib_tag=se&keywords=randy+swaim&qid=1715269499&sprefix=randy+swai%2Caps%2C312&sr=8-1 Listen to us live on mytuner-radio, onlineradiobox, fmradiofree.com and streema.com (the simpleradio app)https://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+networkhttps://www.fmradiofree.com/search?q=professional+podcast+networkhttps://streema.com/radios/search/?q=podcast+business+news+network

"What if failure isn't a flaw, but a feature of our human learning system?"In this episode of Business is Human, Rebecca Fleetwood Hession explores how shame and performance-driven identities can distort our future and block authentic growth. Instead of striving for perfection, Rebecca invites us to see failure as a sacred curriculum, the very path to wisdom, resilience, and purpose.Drawing from both neuroscience and scripture, she reframes the way we relate to setbacks in business and life, showing how reflection, not regret, is the path to character and calling.In this episode, you'll learn:How shame traps the brain in survival mode,  and how stillness helps rewire it for growth.Why reframing failure fuels dopamine and neuroplasticity better than success alone.A spiritual and scientific approach to letting go of guilt and embracing your true identity.Things to listen for:(00:00) Intro(00:51) The power of letting go of shame(01:41) The trap of perfectionism in business(03:43) Embracing failure as a feature(04:28) Spiritual awakening and presence(08:40) The impact of shame on the brain(11:50) Biblical examples of redemption(17:47) Reframing failure in business(23:00) The role of dopamine in learningConnect with Rebecca:https://www.rebeccafleetwoodhession.com/Free webinars - New dates added continually: https://shop.standtallinyourstory.com/products/free-webinar-reconnect-recharge-moving-from-disconnected-to-deeply-fulfilledBusiness is Human Masterclass: https://www.rebeccafleetwoodhession.com/businessishumanmasterclass

The guys discuss the death of co-founder and leader of the Beach Boys, is father's day treated as well as mother's day, and who the best sitcom character is...Support the show: https://www.klbjfm.com/mattandbobfm/See omnystudio.com/listener for privacy information.

SCADA applications are responsible for far more than facilitating real-time process monitoring and alarm management. The process history they compile over time is critical to providing the data-driven insights that industry relies on when optimizing their systems to control costs, maximize uptime and increase the life of infrastructure. Modern SCADA systems must ensure data is safe, relevant and easily shareable with a company's own team or third-party reporting solutions, business systems and artificial intelligence (AI) platforms. Control Amplified talked to Chris Little, media relations director, Trihedral Engineering, about straightforward principles to ensure that your SCADA data is ready to go to work.

Send us a textRoyce begins in his home state of Florida where Governor Desantis just signed some good legislation into law, one of which repealed a bad law that cut off gun and ammo sales during states of emergency declarations.Then, the elephant in the room in L.A., as Royce explains how quickly every state could experience this same violence, because the Democrats, rather than condemning it, are openly supporting it.  Second Amendment relevance is glaringly obvious for every peaceable citizen in Los Angeles and the surrounding areas during their state of emergency.Support the showGiveSendGo | Unconstitutional 2A Prosecution of Tate Adamiak Askari Media GroupBuy Paul Eberle's book "Look at the Dirt"Paul Eberle (lookatthedirt.com)The Deadly Path: How Operation Fast & Furious and Bad Lawyers Armed Mexican Cartels: Forcelli, Peter J., MacGregor, Keelin, Murphy, Stephen: 9798888456491: Amazon.com: BooksVoice of the Blue (buzzsprout.com)

Get the book, RIGOR Unveiled: A Video-Enhanced Flipbook to Promote Teacher Expertise in Relationship Building, Instruction, Goals, Organization, and Relevance About The Author   Douglas Fisher, PhD is professor and chair of educational leadership at San Diego State University and a teacher leader at Health Sciences High and Middle College. He has published numerous articles on reading and literacy, differentiated instruction, and curriculum design, as well as books such as The Teacher Clarity Playbook 2/e, Your Introduction to PLC+, The Illustrated Guide to Teacher Credibility, The Teaching Reading Playbook, and Welcome to Teaching!. In 2022, he was inducted into the Reading Hall of Fame by the Literacy Research Association.   This episode of Principal Center Radio is sponsored by IXL, the most widely used online learning and teaching platform for K-12. Discover the power of data-driven instruction in your school with IXL—it gives you everything you need to maximize learning, from a comprehensive curriculum to meaningful school-wide data. Visit IXL.com/center to lead your school towards data-driven excellence today.   

In this episode of the Greenbook Podcast, host Karen Lynch sits down with Kira Greenberg, Senior Manager of Brand Insights for Jameson at Pernod Ricard USA. With a background in anthropology and deep qualitative research, Kira brings a unique perspective to brand strategy and cultural relevance. She shares how storytelling functions not just as a tool for communication but as a foundation for strategic brand decisions.The conversation spans her category shift from media to spirits, working within a multinational matrix, and the nuanced role of AI in modern research. If you're in insights, marketing, or strategy, this episode will leave you thinking differently about how research connects people, culture, and brands.Key Discussion Points:The power of storytelling in strategic brand insightsShifting categories: from Warner Bros. to Pernod RicardCultural nuance and the art of connecting with diverse audiencesAI's evolving role in qualitative research workflowsWhy the future of insights depends on deep strategic partnershipResources & Links:Pernod Ricard USAJameson WhiskeyGreenbook's IIEX North AmericaYou can reach out to Kira Greenberg on LinkedIn.Many thanks to Kira Greenberg for being our guest. Thanks also to our production team and our editor at Big Bad Audio.

Welcome to Sylvan Way and thanks for joining us as we worship Jesus! Wake Up: From Reputation to Relevance - Revelation 3:1-6 Where we seek to Love God, Love Others, and Live on Mission. We are a church that strives to live fully for Jesus, while sharing His story with others. To learn more: sylvanway.com Send us your prayer requests & comments: sylvanway.com/connect To partner with us through giving: sylvanway.

On this episode of the Swell Season Surf Podcast, we ‘talk story' with Chris Gentile, the proprietor of Pilgrim Surf + Supply in Williamsburg, Brooklyn. We dive into Chris' diverse background in woodworking, photography, art, and fashion. We also cover Pilgrim Surf + Supply's upcoming Shapers Residency program featuring renowned shapers like Malcolm Campbell, Christian Beamish, and Rachel Lord. Chris opens up about the cultural and communal aspects of surfing, his approach to shaping boards, and the journey of founding one of the most influential surf shops in New York. We explore some of the highlights and evolution of Pilgrim Surf + Supply, the challenges and rewards of running a surf shop, and the importance of creating valuable and long-lasting products. There are a lot of hilarious anecdotes from years past and looking toward the future. If you surf in NY, this is requisite listening… Enjoy. Go Check out Pilgrims latest and greatest at: https://pilgrimsurfsupply.com/ You can Follow them on Instagram at @pilgrimsurfsupplyThe Swell Season Surf Podcast is recorded by The NewsStand Studio at Rockefeller Center in the heart of Manhattan and is distributed by The Swell Season Surf Radio Network. For more information, you can follow @swellseasonsurfradio on Instagram or go to our website: www.swellseasonsurf.com Music: Artist: Minute MenSong: Shit From an Old NotebookAlbum: Double Nickels on the Dime00:00 Introduction and Guest Overview02:41 Chris Genteel's Surf Etiquette04:57 Pilgrim Surf's Shaping Residency Program09:38 The Art and Culture of Surfboard Shaping29:56 Challenges and Rewards of Running a Surf Shop37:06 Wearing Military-Inspired Fashion37:56 The Relevance of Outdoor Gear in Urban Life40:27 The Importance of Good Employees46:20 Management Style and Employee Relations50:23 Working with Family in Business55:24 Unexpected Success in Japan01:04:55 The Evolution of Pilgrim01:08:30 Surf Shop Beginnings: Challenges and Surprises01:08:58 The Birth of a Surf Community 01:09:53 The Creative Journey: From Art to Surfboards01:10:51 The Vibrant Williamsburg Art Scene01:11:40 The Need for a Core Surf Shop in NYC01:13:49 Opening the Shop: Community and Collaborations01:16:44 Memorable Events and Unexpected Visitors01:24:42 Shaping Surfboards: An Artistic Perspective01:29:37 Exciting New Projects and Future Plans01:33:39 Final Thoughts and FarewellBecome a supporter of this podcast: https://www.spreaker.com/podcast/swell-season-surf-radio--3483504/support.

This week I'm joined by Dr Jan Eppingstall to talk about scaffolding - what it means, how it helps with hoarding recovery, and why our needs for support change over time. We break down practical, emotional, and motivational scaffolding, from therapy and peer support to self-made systems and the way we talk to ourselves. If you've ever wondered how to find the right kind of help without feeling stuck with it forever, this is the episode for you. Buy your copy of Everything You Need to Know About Hoarding by Dr Lynne Drummond at cambridge.org/EverythingHoarding, and get 20% off with the discount code HOARDING20. #ad Explanation of Scaffolding and the Zone of Proximal Development Definition of scaffolding from educational psychology. Origins in Lev Vygotsky's work: helping people accomplish tasks with support. Relevance to hoarding and recovery. Application of Scaffolding to Hoarding Recovery Psychological, cognitive, and emotional elements in hoarding. Physical and organisational skill deficits in people who hoard. Differences and interplay between psychological barriers and practical skills. Illustrating support levels: from high assistance to independence. Personal examples demonstrating that support needs can resurface over time. The Changing Nature of Scaffolding Scaffolding shifts in form and amount as people progress or encounter setbacks. Individualisation: What's supportive for one may not be for another. Types of Scaffolding for Hoarding Recovery External supports: therapists, peers, coaches. Direct instruction and physical assistance. Environmental modifications. Tools and resources. Social encouragement and accountability. Assessing current functioning. Matching support to challenge level (not too easy, not too hard). Gradually reducing support as independence grows. Scaffolding for Neurodivergent Individuals Adjustments for ADHD: Shorter work periods, built-in breaks. Accountability partners and visual reminders/checklists. Adjustments for Autism: Predictable routines. Clear rules and decision trees. Sensory-friendly environments. Executive Function Challenges and Tailored Scaffolding Strategies like breaking down decisions, using templates, "parking lot" systems for deferred decisions. Recognising that executive function can be context-specific and fluctuate. Importance of Emotional Scaffolding Emotional regulation during dehoarding. Need for self-soothing and distress-tolerance skills as support is reduced. Informal and Internal Scaffolding Peer support, self-talk, problem solving, reminders. Adapting systems in the home as a supportive structure. Habituation and Evolvement of Support Systems Reminder fatigue and strategies to combat it (rotating formats, colours, locations). The necessity for systems to evolve as needs and effectiveness change. Mindset Shifts and Realistic Expectations Acceptance that supports may need to be re-engaged during crises or setbacks. Not viewing return to scaffolding as failure - progress and healing aren't linear. Testing assumptions about personal limitations. Re-evaluating and Customising Support Creating, testing, and modifying practical systems in the home with or without outside perspective. Recognising the value of trying new strategies even if initial skepticism exists. Links Zone of Proximal Development The Metaphor of Scaffolding: Its Utility for the Field of Learning Disabilities, Stone, C. Addison, Journal of Learning Disabilities, 0022-2194, July 1, 1998, Vol. 31, Issue 4 Podcast ep 183: ADHD, executive dysfunction and creating hacks and systems to reduce clutter chaos, with Carrie Lagerstedt Money Love podcast Podcast ep 127: Overcoming overspending with Paige Pritchard, Money Coach Come to a Dehoarding Accountability Zoom session: Accountability Booking Form Dr Jan Eppingstall at Stuffology https://www.facebook.com/stuffologyconsulting/ https://twitter.com/stuff_ology https://www.instagram.com/stuff_ology/ Dr Jan Eppingstall on Pinterest Website: Overcome Compulsive Hoarding Become a Dehoarding Darling Submit a topic for the podcast to cover Questions to ask when dehoarding: https://www.overcomecompulsivehoarding.co.uk/podquestions Instagram: @thathoarderpodcast Twitter: @ThatHoarder Mastodon: @ThatHoarder@mastodon.online TikTok: @thathoarderpodcast Facebook: Overcome Compulsive Hoarding with That Hoarder Pinterest: That Hoarder YouTube: Overcome Compulsive Hoarding with That Hoarder Reddit: Overcome Compulsive Hoarding with That Hoarder subreddit Help out: Support this project Sponsor the podcast Subscribe to the podcast Subscribe to the podcast here

In this powerful episode of The P.A.S. Report Podcast, Professor Nick Giordano explores the forgotten legacy of Mercy Otis Warren. She was a fearless writer, satirist, and historian who helped shape the American Revolution. While most history books spotlight the Founding Fathers, Warren's pen proved just as mighty as any musket. Her work influenced public opinion, challenged tyranny, and preserved the ideals of liberty for future generations. Discover how her words swayed a nation, clashed with John Adams, and continue to resonate in today's fight against government overreach.   Episode Highlights: The story of Mercy Otis Warren: political thinker, pamphleteer, and America's first female historian How Warren's sharp satire helped ignite revolutionary sentiment and exposed Loyalist hypocrisy Why her warnings about centralized power and lost liberty still matter in today's political climate

TalkSports HR1 6.5.25 - Chipper Jones seeks relevance in 2025 by Fanrun Radio

Bob Sullivan Prophecy NBW Rapture Kit (New!) The Time is Now Prophecy Conference The Great Last Days Apostasy (Dr. Hixson's new book) NBW Ministries website Newsletter Signup NBW Ministries store Spirit of the False Prophet Audiobook YouTube Rumble Podbean Spirit of the False Prophet Spirit of the Antichrist Volume One Spirit of the Antichrist Volume Two Prophecy, Israel, End Times, Not By Works

https://www.coachingforrelevance.com/https://www.amazon.com/Bring-Freedom-Potential-Overcoming-Soaring-ebook/dp/B0D3BVD1GY/ref=sr_1_1?crid=3TGTLR44A8JNT&dib=eyJ2IjoiMSJ9.-tS4GlU7CqiCwISeIYoHV_Y1sqCG5MioC8ZbYLo38kAM8A2JPTUFRLp0iE4NntW0HsVqZEHupeHX2wieWWjUPbxo39Cw3mao9Hiv4MHq03zLyylIvKZWDVc9SulEwcwXh1mAiMAHexLsWrS2wJnVjgxLpv0wOi4JQIVoWW4h4aYYk509fMxo880flRWiHCF3ldphFkuTU5Ym8NNNjosdDsuoj04Mr3mU8L-niN4409w.v9J0csZcatbaAlDEgPY0pVS3lXV2XahICl8-gkpNayU&dib_tag=se&keywords=randy+swaim&qid=1715269499&sprefix=randy+swai%2Caps%2C312&sr=8-1 Listen to us live on mytuner-radio, onlineradiobox, fmradiofree.com and streema.com (the simpleradio app)https://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+networkhttps://www.fmradiofree.com/search?q=professional+podcast+networkhttps://streema.com/radios/search/?q=podcast+business+news+network

“When we ignore our personal, emotional, and social needs, we end up striving instead of thriving.”In this episode of Business is Human, Rebecca Fleetwood Hession unpacks how the modern obsession with control, metrics, and optimization can disconnect us from what really fuels growth—our authentic human needs. Drawing from neuroscience, scripture, and her coaching experience, Rebecca reveals how striving leads to burnout and fear, while thriving requires alignment with our true identity, emotional awareness, and meaningful connection.In this episode, you'll learn:What striving really means and why it leads to burnoutHow aligning with your authentic self calms your nervous system and fuels creativityThe power of naming emotions and emotional check-ins for better decision-makingThings to listen for:(00:00) Intro(01:09) The struggle between business needs and human needs(02:38) How survival and thriving impact your nervous system(05:17) Personal authenticity and the cost of misalignment(09:40) Resetting your day to shift from striving to thriving(10:43) Emotions as feedback and naming your feelings(14:20) The importance of social connection for nervous system regulation(17:44) Breath work and stillness to build team safety(21:18) Choosing connection over competitionConnect with Rebecca:https://www.rebeccafleetwoodhession.com/

Episode SummaryIn this episode of OnBase, host Chris Moody sits down with Lydia Hutchison for a powerful conversation on what works in modern B2B prospecting. Lydia explains why typical AI-personalized messages fail to cut through and how relevance, rooted in deep customer understanding, wins every time.She unpacks her triple-touch framework, the value of tone and timing, and the human psychology that underpins effective outreach. Lydia also reveals her favorite high-converting tactic that combines manual research with real-time relevance. If you're struggling with connect rates, sequence performance, or objection handling, this episode offers a fresh, actionable perspective.Key TakeawaysRelevance Trumps Personalization: Generic personalization wastes the prospect's time. Relevance speaks directly to their daily pain and success metrics—and that's what drives replies.Triple-Touch Strategy Works: Lydia advocates a three-channel approach—phone, LinkedIn, email—for testing message resonance and adjusting in real-time based on feedback.Lead with Psychology, Not Scripts: Authentic, thoughtful outreach begins with understanding how people accomplish their tasks—and how you can help them do it more effectively.Objections Aren't Always Real: Recognize the difference between a true objection and simple disinterest. Learn to use tone, timing, and multichannel follow-up to stay human and helpful.AI is a Research Assistant, Not a Salesperson: When used well, AI can support better outreach by helping reps research personas and challenges, but it shouldn't write your messages for you.Quotes“Everybody is getting their job done without you. So your job is to show them how to do it better—not tell them they're doing it wrong.”Best Moments (0:56) Lydia Hutchison's Journey into Sales (2:59)Developing Expertise in Sales Execution and Prospecting  (8:00) Differentiating Relevance and Personalization in Prospecting(12:09) Key Factors to Make a Sales Message Stand Out (14:19) Example of Focusing on Relevance Over Personalization (16:27) Process for Ensuring Consistent and Compelling Messaging Across Sales Teams(18:34) Approaching Objection Handling (20:33) Actionable Advice for Struggling Prospecting Teams Shout-outsJason Bay – Lydia recommends Jason for practical advice on sales openers and messaging, especially for go-to-market teams. His content helps reps connect more effectively with prospects.Jen Allen-Knuth- Jen's focus on the psychology of sales resonates with Lydia. She recommends Jen's insightful LinkedIn posts on buyer behavior and objection handling.About the GuestLydia Hutchison is the Head of Business Development at DataHub. She is a data-obsessed sales leader, builder of outbound sales motions, from early-stage startups to global enterprises. Lydia is passionate about coaching for success and empowering sales development orgs to crush their revenue and career goals.Website: datahub.comConnect with Lydia.

In this episode of Case Studies, Casey is joined by Stephen M.R. Covey; bestselling author of The Speed of Trust and one of today's most respected thinkers on leadership and credibility. Together, they explore the one leadership trait that multiplies everything it touches; and the silent killer when it's missing: trust.Stephen reveals why trust isn't just a soft skill, but the core of every high-performing team and thriving organization. He breaks down his legendary Four Cores of Credibility; integrity, intent, capabilities, and results; and shows how this framework can diagnose and transform relationships, leadership effectiveness, and organizational culture.From elite sports to billion-dollar businesses to moments of parenting and personal growth, Stephen and Casey unpack how trust scales performance, attracts talent, and builds enduring influence. They also dive deep into stories from Stephen's upbringing as the son of Stephen R. Covey; giving a behind-the-scenes look at the principles that shaped a global legacy.If you lead, influence, or build; this conversation will challenge and elevate how you think about the most underestimated force in leadership.00:00 – 00:45 | Introduction & Legacy Connection00:45 – 02:30 | The Relevance of Principles in the AI Era02:30 – 05:15 | The One Leadership Trait That Changes Everything05:15 – 09:00 | The Four Cores of Credibility09:00 – 13:08 | Character vs Competence in Trust13:08 – 18:33 | Real-World Examples: Trust on the Field & in Business18:33 – 23:40 | Strengths-Based Leadership & Avoiding Sinking Boats23:40 – 29:48 | Systems That Break Trust29:48 – 36:41 | The Cost of Mistrust in Organizations36:41 – 41:56 | Teaching Principles Through Story & Experience41:56 – 46:52 | Modeling Integrity with Small Decisions46:52 – 52:11 | Parenting with Purpose & Prioritizing Values52:11 – 58:30 | Saying No with Elegance & Clarity58:30 – 01:07:36 | Lessons in Time, Presence & Emotional Bank Accounts01:07:36 – 01:11:57 | Green & Clean: A Trust Lesson from Age 7 Hosted on Acast. See acast.com/privacy for more information.

Don't get to the end of this year wishing you had taken action to change your business and your life.Click here to schedule a free discovery call for your business: https://geni.us/IFORABEShop-Ware gives you the tools to provide your shop with everything needed to become optimally profitable.Click here to schedule a free demo: https://info.shop-ware.com/profitabilityTransform your shop's marketing with the best in the automotive industry, Shop Marketing Pros!Get a free audit of your shop's current marketing by clicking here: https://geni.us/ShopMarketingPros Shop owners, are you ready to simplify your business operations? Meet 360 Payments, your one-stop solution for effortless payment processing.Imagine this—no more juggling receipts, staplers, or endless paperwork. With 360 Payments, you get everything integrated into one sleek, digital platform.Simplify payments. Streamline operations. Check out 360payments.com today!In this episode, Lucas and David are joined by Vlad Shishkaryov, founder of Bridge Learning Tech. Vlad dives into the evolution of technical training in the automotive industry, emphasizing the importance of creating engaging, high-fidelity training content that adapts to shorter attention spans. The conversation explores the challenges and limitations of virtual and augmented reality training tools and highlights the need for scalable, accessible solutions that don't require costly new equipment. Vlad also discusses the ongoing struggle to build customer trust in automotive service and how innovative training and transparent practices can help bridge the gap between legacy and newer technicians.00:00 Engaging Training Techniques with AI03:19 "Education's Relevance in Tech Era"08:01 AR/VR Training Cost Concerns12:37 Challenges in Technician Training Buy-In16:24 "Incentives Crucial for Technician Jobs"17:35 Wiring Glitch Causes Fan Malfunction20:05 Surveillance and Intrigue in Pakistan25:58 Expanding EV Safety Certification Outreach29:32 Streamlined Digital Learning for Certification31:13 From Kia to Consultancy35:42 Overcoming Complex Dealer Pay Plans37:01 "Video Tech Enhances Auto Inspections"41:43 Dealership Service Contract Dispute45:09 Finance Training: Manipulation and Omission47:49 Ongoing FCA Case and Consumer Impact52:18 "Leap Forward Podcast Launch"55:21 Calibration Practices Debate in Auto Shops57:03 "Solving Communication and Trust Issues"

“Data gives us clarity, but without vision, it can also lead us straight into confusion, fear, and burnout.”In this episode of Business is Human, Rebecca Fleetwood Hession unpacks how the modern workplace obsession with data can quietly disconnect us from purpose, progress, and people. Drawing from neuroscience, scripture, and her years as a coach and consultant, Rebecca explains how a relentless focus on analytics can put our nervous system into overdrive, and shut down the creativity and intuition we desperately need to lead well.Whether you're a manager overwhelmed by spreadsheet demands or a leader asking for one more dashboard to feel in control, Rebecca makes the case for returning to a more faith driven way of decision making. She reminds us that it wasn't spreadsheets that parted the Red Sea, it was vision, belief, and divine guidance.In this episode, you'll learn:How to recognize fear-driven leadership patterns masked as controlWhat neuroscience says about balancing analysis with intuitionActionable ways to reconnect to your purpose, your team, and your faithThings to listen for:(00:00) Intro(00:43) 90-Day summer reset program(01:25) The pitfalls of data overload(05:34) Balancing data with vision and intuition(11:20) Practical action plans for leaders(16:19) Measure your life by what God can achieveConnect with Rebecca:https://www.rebeccafleetwoodhession.com/

In this fascinating episode of Guerrilla History, we bring on Kit Klarenberg of The Grayzone to discuss the NATO campaign against Yugoslavia, its relevance to today, and the delusion of US air power!  We are also lucky to be joined by Nemanja Lukić as a guest host for this episode.  In addition to being a keen analyst (and former guest of Guerrilla History), Nemanja personally lived through the bombing campaign.  This is a terrific discussion with plenty of history, analysis, and connections being drawn between this event of the past and the ongoing genocide in Gaza.  This is an important one, you won't want to miss a minute! Kit Klarenberg is an investigative journalist and the UK Lead at The Grayzone.  He also runs his personal site Global Delinquents and can be found on twitter @KitKlarenberg. Nemanja Lukić is a Yugoslav anti-imperialist activist who runs the Anti-Imperialist Network website. You can also follow Anti-Imp Net on twitter @antiimpnet.  Additionally, you should check out the article that Nemanja mentioned that he coauthored with our friend (and former guest) Alejandro Pedregal here. Help support the show by signing up to our patreon, where you also will get bonus content: https://www.patreon.com/guerrillahistory